Erratum: Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures

Soraya Curiel-Olmo; Almudena García-Castaño; Rebeca Vidal; Helena Pisonero; Ignacio Varela; Alicia León-Castillo; Eugenio Trillo; Carmen González-Vela; Nuria García-Diaz; Carmen Almaraz; Thaidy Moreno; Laura Cereceda; Rebeca Madureira; Nerea Martinez; Pablo Ortiz-Romero; Elsa Valdizán; Miguel Angel Piris; José Pedro Vaqué

doi:10.18632/oncotarget.7118

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Erratum: Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures

Soraya Curiel-Olmo, Almudena García-Castaño, Rebeca Vidal, Helena Pisonero, Ignacio Varela, Alicia León-Castillo, Eugenio Trillo, Carmen González-Vela, Nuria García-Diaz, Carmen Almaraz, Thaidy Moreno, Laura Cereceda, Rebeca Madureira, Nerea Martinez, Pablo Ortiz-Romero, Elsa Valdizán, Miguel Angel Piris and José Pedro Vaqué _

PDF | How to cite

Oncotarget. 2016; 7:6352. https://doi.org/10.18632/oncotarget.7118

Metrics: PDF 2567 views | ?

Present: Due to a technical error, the following author names were indexed incorrectly in PubMed: Piris MA and Vaqué JP

Correct: The abbreviation has been updated to reflect correct spelling of these authors’ names. The publisher sincerely apologizes for this oversight

Original article: Oncotarget. 2015; 6: 25452-25465. DOI: 10.18632/oncotarget.4545

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7118

Publication Alerts

Corrections:

Erratum: Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures